Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0OA5G
|
||||
| Former ID |
DCL000006
|
||||
| Drug Name |
SNS-314
|
||||
| Synonyms |
AK2; SN-314
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [522092] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Sunesis Pharma
|
||||
| Formula |
C18H15ClN6OS2
|
||||
| Canonical SMILES |
C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4
|
||||
| InChI |
1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)
|
||||
| InChIKey |
FAYAUAZLLLJJGH-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 1057249-41-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
56464763, 57654852, 80963129, 99443832, 103905586, 123092438, 124950687, 134338722, 135298932, 135685410, 135685411, 135685429, 137884076, 152344036, 160968444, 162772363, 177748743, 180387003, 185985029, 198969974, 202829292, 229434728, 246827038, 252216324, 252443026, 252450737, 252481011, 252543353
|
||||
| Target and Pathway | |||||
| Target(s) | Aurora protein kinase | Target Info | Inhibitor | [537044], [537212], [537234], [537635] | |
| Aurora kinase A | Target Info | Inhibitor | [537044], [537212], [537234], [537635] | ||
| Aurora kinase B | Target Info | Inhibitor | [537044], [537212], [537234], [537635] | ||
| KEGG Pathway | Oocyte meiosishsa04114:Oocyte meiosis | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
| Separation of Sister Chromatids | |||||
| Resolution of Sister Chromatid Cohesion | |||||
| RHO GTPases Activate ForminsR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||||
| Regulation of PLK1 Activity at G2/M TransitionR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||||
| RHO GTPases Activate Formins | |||||
| Mitotic Prometaphase | |||||
| WikiPathways | EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | |||||
| Gastric Cancer Network 1 | |||||
| Integrated Breast Cancer Pathway | |||||
| APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway | |||||
| APC/C-mediated degradation of cell cycle proteinsWP2757:Mitotic Metaphase and Anaphase | |||||
| Mitotic Prometaphase | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| References | |||||
| Ref 537044 | Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1409-12. Epub 2009 Jan 19. | ||||
| Ref 537212 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. | ||||
| Ref 537234 | The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009 Apr;8(4):930-9. | ||||
| Ref 537635 | SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2009 Aug 1. | ||||